CA3008809A1 - Antibodies to risperidone and use thereof - Google Patents

Antibodies to risperidone and use thereof Download PDF

Info

Publication number
CA3008809A1
CA3008809A1 CA3008809A CA3008809A CA3008809A1 CA 3008809 A1 CA3008809 A1 CA 3008809A1 CA 3008809 A CA3008809 A CA 3008809A CA 3008809 A CA3008809 A CA 3008809A CA 3008809 A1 CA3008809 A1 CA 3008809A1
Authority
CA
Canada
Prior art keywords
antibody
seq
risperidone
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3008809A
Other languages
English (en)
French (fr)
Inventor
Banumathi Sankaran
Thomas R. DECORY
Theresa TUBBS
Linda COLT
Maarten VLIEGEN
Pieter Rik HASPESLAGH
Eric Hryhorenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saladax Biomedical Inc
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3008809A1 publication Critical patent/CA3008809A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA3008809A 2015-12-17 2016-12-15 Antibodies to risperidone and use thereof Abandoned CA3008809A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268898P 2015-12-17 2015-12-17
US62/268,898 2015-12-17
PCT/US2016/066931 WO2017106501A1 (en) 2015-12-17 2016-12-15 Antibodies to risperidone and use thereof

Publications (1)

Publication Number Publication Date
CA3008809A1 true CA3008809A1 (en) 2017-06-22

Family

ID=57708858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3008809A Abandoned CA3008809A1 (en) 2015-12-17 2016-12-15 Antibodies to risperidone and use thereof

Country Status (8)

Country Link
US (2) US10444250B2 (https=)
EP (1) EP3390449A1 (https=)
JP (1) JP6949025B2 (https=)
CN (1) CN108431040B (https=)
AU (1) AU2016372069A1 (https=)
CA (1) CA3008809A1 (https=)
MA (1) MA44056A (https=)
WO (1) WO2017106501A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
CN104736565B (zh) * 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
CN112730825B (zh) * 2020-12-17 2022-09-06 北京丹大生物技术有限公司 一种用于检测利培酮和/或9-羟基利培酮的检测试剂和检测试剂盒
CN115927347B (zh) * 2022-10-14 2026-01-16 杭州佰辰医学检验所有限公司 特异性结合利培酮的核酸适配体及衍生物、应用、试剂盒

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
DE69232002T2 (de) 1991-06-07 2002-06-06 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays unter Verwendung von markierten Hapten-Analogen
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DK0582368T3 (da) 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
CA2192467C (en) 1994-06-10 2009-03-31 Alireza Rezaie Calcium binding recombinant antibody against protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
AU8148898A (en) 1997-06-23 1999-01-04 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
DE60335428D1 (de) 2002-01-31 2011-02-03 Randox Lab Ltd Immunogene, Antikörper und Konjugate für Ketamin und dessen Metaboliten
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2003217936A1 (en) 2002-03-28 2003-10-13 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
AU2003259256A1 (en) 2002-07-29 2004-02-16 Potomac Pharma, LLC. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
US7271252B2 (en) 2003-04-22 2007-09-18 Roche Diagnostics Operations, Inc. Reagents for detecting efavirenz
CA2525251C (en) 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
BRPI0413595B8 (pt) 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
ES2335589T3 (es) 2003-09-23 2010-03-30 Fermion Oy Preparacion de quetiapina.
CN101921279A (zh) 2003-10-01 2010-12-22 阿得罗公司 螺环杂环衍生物及其应用方法
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
DE602004024236D1 (en) 2003-12-12 2009-12-31 Inverness Medical Switzerland Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (ja) 2004-04-26 2005-11-03 Takami Matsuyama 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
JP2010507648A (ja) 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸ｎｍｄａ活性を有する新規向精神薬
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
JP5632582B2 (ja) 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
WO2008087557A2 (en) 2007-01-08 2008-07-24 Actavis Group Ptc Ehf An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
CN101245065B (zh) 2007-02-14 2010-05-19 江苏恩华药业股份有限公司 制备苯并异噁唑衍生物的方法及其中间体
RU2010116351A (ru) 2007-09-27 2012-05-20 Новартис АГ (CH) Мониторинг лекарственных средств
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
CN102245605B (zh) 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
EP2347015A4 (en) 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
EP2389169A1 (en) 2009-01-26 2011-11-30 Egalet A/S Controlled release formulations with continuous efficacy
EP2406289B1 (en) 2009-03-10 2017-02-22 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
CN102573913B (zh) 2009-07-31 2014-06-18 阿森迪斯药物股份有限公司 可生物降解的基于聚乙二醇的水不溶性水凝胶
CN102574917A (zh) 2009-08-17 2012-07-11 株式会社未来创药研究所 含有抗hb-egf抗体作为有效成分的药物组合物
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
EP3476218A1 (en) 2010-03-11 2019-05-01 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
SG11201501130PA (en) 2012-08-16 2015-04-29 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
CA2882490A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
ES2822907T3 (es) 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de quetiapina para su uso en inmunoensayos
TR201816378T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Olanzapin haptenleri.
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
ES2904838T3 (es) * 2012-08-21 2022-04-06 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
ES2978909T3 (es) * 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof

Also Published As

Publication number Publication date
MA44056A (fr) 2018-10-24
JP2019504013A (ja) 2019-02-14
US20170176473A1 (en) 2017-06-22
CN108431040B (zh) 2022-07-26
JP6949025B2 (ja) 2021-10-13
US20200033370A1 (en) 2020-01-30
US10852313B2 (en) 2020-12-01
EP3390449A1 (en) 2018-10-24
CN108431040A (zh) 2018-08-21
US10444250B2 (en) 2019-10-15
AU2016372069A1 (en) 2018-06-07
WO2017106501A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
EP3354751B1 (en) Antibodies to aripiprazole and use thereof
EP3333195B1 (en) Antibodies to quetiapine and use thereof
EP2888593B1 (en) Antibodies to risperidone and use thereof
EP2888590B1 (en) Antibodies to olanzapine and use thereof
US10852313B2 (en) Antibodies to risperidone and use thereof
US11104742B2 (en) Antibodies to quetiapine and use thereof
WO2014031630A2 (en) Antibodies to paliperidone and use thereof
HK40031844A (en) Antibodies to aripiprazole and use thereof
HK1255219B (en) Antibodies to quetiapine and use thereof
HK1260330B (en) Antibodies to aripiprazole and use thereof
HK1211989B (en) Antibodies to aripiprazole and use thereof
HK1212035B (en) Antibodies to quetiapine and use thereof
HK1212033B (en) Antibodies to olanzapine and use thereof
HK1212034B (en) Antibodies to risperidone and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211202

FZDE Discontinued

Effective date: 20240417